---
title: "12 Health Care Stocks Moving In Monday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294721264.md"
description: "During Monday's intraday session, several healthcare stocks experienced significant volatility. Gainers included Universe Pharmaceuticals (UPC), which surged 108.5% to $6.59, and SL Science Holding (SLBT), up 27.89%. Other notable gainers were Bristol-Myers Squibb Celegne Rights (CELGR) and Autolus Therapeutics (AUTL). On the losing side, CalciMedica (CALC) dropped 21.4%, followed by NewGenIvf Group (NIVF) and Genprex (GNPX). The report highlights substantial price movements across various market capitalizations in the healthcare sector."
datetime: "2026-08-03T17:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294721264.md)
  - [en](https://longbridge.com/en/news/294721264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294721264.md)
---

# 12 Health Care Stocks Moving In Monday's Intraday Session

### Gainers

-   **Universe Pharmaceuticals** (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million.
-   **SL Science Holding** (NASDAQ:SLBT) stock rose 27.89% to $3.38. The market value of their outstanding shares is at $1.4 billion.
-   **Bristol-Myers Squibb Company Celegne Contingent Value Rights** (NYSE:CELGR) stock rose 27.65% to $0.12.
-   **Autolus Therapeutics** (NASDAQ:AUTL) shares moved upwards by 25.16% to $1.86. The company's market cap stands at $396.5 million.
-   **Beyond Air** (NASDAQ:XAIR) stock rose 23.79% to $6.53. The market value of their outstanding shares is at $3.8 million.
-   **Camp4 Therapeutics** (NASDAQ:CAMP) stock moved upwards by 21.73% to $4.2. The company's market cap stands at $179.1 million.

### Losers

-   **CalciMedica** (NASDAQ:CALC) shares declined by 21.4% to $0.79 during Monday's regular session. The market value of their outstanding shares is at $15.7 million.
-   **NewGenIvf Group** (NASDAQ:NIVF) stock decreased by 17.71% to $0.67. The market value of their outstanding shares is at $2.7 million.
-   **Genprex** (NASDAQ:GNPX) shares declined by 16.53% to $5.0. The market value of their outstanding shares is at $3.0 million.
-   **Fortress Biotech** (NASDAQ:FBIO) stock decreased by 15.34% to $2.65. The market value of their outstanding shares is at $103.9 million.
-   **Moleculin Biotech** (NASDAQ:MBRX) shares decreased by 13.91% to $0.34. The market value of their outstanding shares is at $2.1 million.
-   **Shuttle Pharmaceuticals** (NASDAQ:SHPH) stock declined by 12.9% to $3.31. The market value of their outstanding shares is at $2.2 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [UPC.US](https://longbridge.com/en/quote/UPC.US.md)
- [GNPX.US](https://longbridge.com/en/quote/GNPX.US.md)
- [CALC.US](https://longbridge.com/en/quote/CALC.US.md)
- [AUTL.US](https://longbridge.com/en/quote/AUTL.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [NIVF.US](https://longbridge.com/en/quote/NIVF.US.md)
- [SLBT.US](https://longbridge.com/en/quote/SLBT.US.md)
- [XAIR.US](https://longbridge.com/en/quote/XAIR.US.md)
- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)
- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [SHPH.US](https://longbridge.com/en/quote/SHPH.US.md)
- [NIVFW.US](https://longbridge.com/en/quote/NIVFW.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Bristol-Myers Squibb announces dividend of R$ 2.11 per unit for Q3 2026](https://longbridge.com/en/news/294825420.md)
- [Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That](https://longbridge.com/en/news/294582182.md)
- [BUZZ-Street View: Bristol Myers keeps the ball rolling on growth and pipeline promise](https://longbridge.com/en/news/294509257.md)
- [Earnings snapshot: BMY boosts outlook; Eliquis demand growth tempered by generic competition in legacy portfolio](https://longbridge.com/en/news/294356448.md)
- [Why Is Bristol-Myers Squibb Stock Surging Monday?](https://longbridge.com/en/news/294697898.md)